Brief: David Apelian Takes Helm As CEO at Eiger Biopharmaceuticals

Eiger Biopharmaceuticals

29/06/2023 14:30

June 29 (Reuters) - Eiger BioPharmaceuticals Inc
 EIGR.O :
    * EIGER BIOPHARMACEUTICALS TO FOCUS ON METABOLIC DISEASES
WITH
AVEXITIDE; DAVID APELIAN TAKES HELM AS CEO
    * EIGER BIOPHARMACEUTICALS INC - PRIORITIZING RESOURCES TO
ADVANCE
AVEXITIDE IN HYPERINSULINEMIC HYPOGLYCEMIA INDICATIONS
    * EIGER BIOPHARMACEUTICALS INC - ACTIVE DISCUSSIONS UNDERWAY
WITH
POTENTIAL PARTNERS TO ADVANCE LATE-STAGE VIROLOGY PROGRAMS
    * EIGER BIOPHARMACEUTICALS INC - REDUCTION IN WORKFORCE
EXECUTED
TO ALIGN WITH FOCUS ON AVEXITIDE; EXTENDS CASH RUNWAY TO Q4 2024
    * EIGER BIOPHARMACEUTICALS INC - EVALUATING STRATEGIC
PARTNERING
OPTIONS FOR ITS VIROLOGY ASSETS, LONAFARNIB AND PEGINTERFERON
LAMBDA
    * EIGER BIOPHARMACEUTICALS-  25% REDUCTION IN WORKFORCE,
SPENDING
RELATED TO HDV DEVELOPMENT PROGRAM, TERM LOAN TO EXTEND CASH
RUNWAY INTO Q4 OF 2024

Source text for Eikon:  ID:nPn98Gm3Ma 
Further company coverage:  EIGR.O